Russian, Korean Pharmas Lead $42.5M Argos Financing, Take Local Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
The personalized immunotherapy developer partnered with two foreign pharmas but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.